These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

437 related items for PubMed ID: 15639704

  • 1. Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase.
    Warren E, Ward S, Gordois A, Scuffham P.
    Clin Ther; 2004 Nov; 26(11):1924-33. PubMed ID: 15639704
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.
    Reed SD, Anstrom KJ, Ludmer JA, Glendenning GA, Schulman KA.
    Cancer; 2004 Dec 01; 101(11):2574-83. PubMed ID: 15493042
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness study comparing imatinib with interferon-alpha for patients with newly diagnosed chronic-phase (CP) chronic myeloid leukemia (CML) from the Chinese public health-care system perspective (CPHSP).
    Chen Z, Wang C, Xu X, Feng W.
    Value Health; 2009 Dec 01; 12 Suppl 3():S85-8. PubMed ID: 20586990
    [Abstract] [Full Text] [Related]

  • 4. Cost-utility analysis of imatinib mesilate for the treatment of advanced stage chronic myeloid leukaemia.
    Gordois A, Scuffham P, Warren E, Ward S.
    Br J Cancer; 2003 Aug 18; 89(4):634-40. PubMed ID: 12915870
    [Abstract] [Full Text] [Related]

  • 5. Cost utility of allogeneic stem cell transplantation with matched unrelated donor versus treatment with imatinib for adult patients with newly diagnosed chronic myeloid leukaemia.
    Breitscheidel L.
    J Med Econ; 2008 Aug 18; 11(4):571-84. PubMed ID: 19450068
    [Abstract] [Full Text] [Related]

  • 6. Cost-efficacy of imatinib versus allogeneic bone marrow transplantation with a matched unrelated donor in the treatment of chronic myelogenous leukemia: a decision-analytic approach.
    Skrepnek GH, Ballard EE.
    Pharmacotherapy; 2005 Mar 18; 25(3):325-34. PubMed ID: 15843279
    [Abstract] [Full Text] [Related]

  • 7. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
    Kantarjian H, O'Brien S, Cortes J, Shan J, Giles F, Garcia-Manero G, Verstovsek S, Faderl S, Rios MB, Talpaz M.
    Cancer; 2003 Oct 01; 98(7):1430-7. PubMed ID: 14508830
    [Abstract] [Full Text] [Related]

  • 8. Is imatinib a cost-effective treatment for newly diagnosed chronic myeloid leukemia patients?
    Goldman J.
    Nat Clin Pract Oncol; 2005 Mar 01; 2(3):126-7. PubMed ID: 16264901
    [No Abstract] [Full Text] [Related]

  • 9. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
    Kantarjian HM, O'Brien S, Cortes J, Giles FJ, Rios MB, Shan J, Faderl S, Garcia-Manero G, Ferrajoli A, Verstovsek S, Wierda W, Keating M, Talpaz M.
    Cancer; 2003 Dec 15; 98(12):2636-42. PubMed ID: 14669283
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of dasatinib versus high-dose imatinib in patients with Chronic Myeloid Leukemia (CML), resistant to standard dose imatinib--a Swedish model application.
    Ghatnekar O, Hjalte F, Taylor M.
    Acta Oncol; 2010 Aug 15; 49(6):851-8. PubMed ID: 20615173
    [Abstract] [Full Text] [Related]

  • 11. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
    Cortes J, Talpaz M, O'Brien S, Giles F, Beth Rios M, Shan J, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Kantarjian H.
    Cancer; 2003 Sep 15; 98(6):1105-13. PubMed ID: 12973833
    [Abstract] [Full Text] [Related]

  • 12. Cost effectiveness of imatinib compared with interferon-alpha or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia.
    Dalziel K, Round A, Garside R, Stein K.
    Pharmacoeconomics; 2005 Sep 15; 23(5):515-26. PubMed ID: 15896102
    [Abstract] [Full Text] [Related]

  • 13. Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis.
    Dalziel K, Round A, Stein K, Garside R, Price A.
    Health Technol Assess; 2004 Jul 15; 8(28):iii, 1-120. PubMed ID: 15245690
    [Abstract] [Full Text] [Related]

  • 14. Long-term survival estimates for imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.
    Anstrom KJ, Reed SD, Allen AS, Glendenning GA, Schulman KA.
    Cancer; 2004 Dec 01; 101(11):2584-92. PubMed ID: 15493041
    [Abstract] [Full Text] [Related]

  • 15. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
    Iacobucci I, Rosti G, Amabile M, Poerio A, Soverini S, Cilloni D, Testoni N, Abruzzese E, Montefusco E, Ottaviani E, Iuliano F, Russo D, Gobbi M, Alimena G, Martino B, Terragna C, Pane F, Saglio G, Baccarani M, Martinelli G.
    J Clin Oncol; 2006 Jan 20; 24(3):454-9. PubMed ID: 16421422
    [Abstract] [Full Text] [Related]

  • 16. Imatinib mesylate in Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon alpha.
    Tóthová E, Kafková A, Fricová M, Benová B, Kirschnerová G, Tóthová A.
    Neoplasma; 2005 Jan 20; 52(1):63-7. PubMed ID: 15739029
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States.
    Sanon M, Taylor DC, Parthan A, Coombs J, Paolantonio M, Sasane M.
    J Med Econ; 2013 Jan 20; 16(1):150-9. PubMed ID: 22762291
    [Abstract] [Full Text] [Related]

  • 18. Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemias.
    Kantarjian HM, Talpaz M.
    Semin Oncol; 2001 Oct 20; 28(5 Suppl 17):9-18. PubMed ID: 11740802
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.